Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 221-230 of 284 for

Edit search filters
  1. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

    Jacksonville, FL, Rochester, MN

  2. Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

    Scottsdale/Phoenix, AZ, La Crosse, WI

  3. A Study to Evaluate Hormone Concentrations in Patients with Metastatic Cancer

    Rochester, MN

  4. Shared Decision-Making Encounter Tool for Decisions of Adjuvant Treatment in Patients with Resected Non-Small Cell Lung Cancer

    Rochester, MN

  5. Understanding the Contents of Exhaled Breath in Health and Disease

    Rochester, MN

  6. Spatial and Molecular Architecture of Tumor Environments Responsive to IO (immuno-oncology) Therapy

    Rochester, MN

  7. Cell Free DNA (Cfdna) Blood Assays for the Detection of EGFR and Other Clinically Relevant Gene Mutations in Patients with Non-Small Cell Lung Cancer

    Rochester, MN

  8. Preclinical drug testing and assay development for lung adenocarcinoma characterized by the expression of ASCL1

    Rochester, MN

  9. A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors

    Rochester, MN

  10. A Study of Pharmacogenomics Results and Clinical Data of Patients with Chronic Myeloid Leukemia and Lung Cancer to Assess Current and Future Therapeutic Relevance

    Rochester, MN

.

Mayo Clinic Footer